Ozempic Nation Paradigm Shift or Public Health Mirage Review Abstract The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin-based therapies has transformed the management of obesity and type 2 diabetes mellitus. Semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, initiated a major shift in
Tag: ozempic
Semaglutide Use Shows Bonus Benefit Of Osteoarthritis Risk Reduction
Semaglutide Use Shows Bonus Benefit Of Osteoarthritis Risk Reduction Overview Osteoarthritis (OA) is a widespread degenerative joint condition. While the influence of obesity on OA is well-established, the effect of semaglutide on OA remains less understood. The objective was to evaluate the effect of semaglutide on the risk of OA among patients with
